Hormonal therapy induces an increase in AR−CXCR2+ neuroendocrine cancer cells in prostate tumors [170] which causes the survival of AR+ luminal cancer cells during subsequent doses of hormonal therapy. The gene discussed is AR; the disease is neuroendocrine carcinoma.